Maeve Jones-O'Connor1,2, Pradeep Natarajan3,4,5,6. 1. Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. 2. Department of Medicine, Harvard Medical School, Boston, MA, USA. 3. Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. pnatarajan@mgh.harvard.edu. 4. Department of Medicine, Harvard Medical School, Boston, MA, USA. pnatarajan@mgh.harvard.edu. 5. Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. pnatarajan@mgh.harvard.edu. 6. Program in Medical and Population Genetics, Broad Institute of Harvard & MIT, Cambridge, MA, USA. pnatarajan@mgh.harvard.edu.
Abstract
PURPOSE OF REVIEW: Cardiovascular disease (CVD) remains the leading cause of death worldwide, with coronary artery disease (CAD) responsible for the vast majority of these deaths. Incidence is increasing in developing countries, and prevalence is increasing globally as populations age. Once CAD is manifest, recurrent event risk remains high. RECENT FINDINGS: Multiple therapeutic avenues have had significant recent developments, including diet, low-density lipoprotein cholesterol management, triglycerides, hypoglycemic agents, antiplatelet agents, and oral anticoagulants. Combined approaches involving specific, tailored lifestyle, and pharmacological interventions will provide the most effective strategy for reducing the risk of recurrent CVD events. Here, we review risk prediction and non-invasive non-pharmacologic and pharmacologic approaches to mitigate residual coronary artery disease risk.
PURPOSE OF REVIEW: Cardiovascular disease (CVD) remains the leading cause of death worldwide, with coronary artery disease (CAD) responsible for the vast majority of these deaths. Incidence is increasing in developing countries, and prevalence is increasing globally as populations age. Once CAD is manifest, recurrent event risk remains high. RECENT FINDINGS: Multiple therapeutic avenues have had significant recent developments, including diet, low-density lipoprotein cholesterol management, triglycerides, hypoglycemic agents, antiplatelet agents, and oral anticoagulants. Combined approaches involving specific, tailored lifestyle, and pharmacological interventions will provide the most effective strategy for reducing the risk of recurrent CVD events. Here, we review risk prediction and non-invasive non-pharmacologic and pharmacologic approaches to mitigate residual coronary artery disease risk.
Authors: G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern Journal: JAMA Date: 2001-04-04 Impact factor: 56.272
Authors: J A Iestra; D Kromhout; Y T van der Schouw; D E Grobbee; H C Boshuizen; W A van Staveren Journal: Circulation Date: 2005-08-09 Impact factor: 29.690
Authors: Shirya Rashid; David E Curtis; Rita Garuti; Norma N Anderson; Yuriy Bashmakov; Y K Ho; Robert E Hammer; Young-Ah Moon; Jay D Horton Journal: Proc Natl Acad Sci U S A Date: 2005-04-01 Impact factor: 11.205
Authors: William E Kraus; Joseph A Houmard; Brian D Duscha; Kenneth J Knetzger; Michelle B Wharton; Jennifer S McCartney; Connie W Bales; Sarah Henes; Gregory P Samsa; James D Otvos; Krishnaji R Kulkarni; Cris A Slentz Journal: N Engl J Med Date: 2002-11-07 Impact factor: 91.245
Authors: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene Journal: N Engl J Med Date: 2004-03-08 Impact factor: 91.245